In a 75-year-old man receiving testosterone replacement therapy (200 mg testosterone enanthate every two weeks) with free testosterone 203 pg/mL, total testosterone 889 ng/dL, and estradiol 43 pg/mL, what further workup and treatment adjustments are recommended?

Reduce Testosterone Dose Immediately

This patient's total testosterone of 889 ng/dL exceeds the target mid-normal range (400-700 ng/dL) recommended by Endocrine Society guidelines, and the dose should be reduced to achieve levels in the mid-normal range. 1

Immediate Dose Adjustment

The current regimen of 200 mg every 2 weeks is producing supraphysiologic testosterone levels. Reduce to 100 mg every 2 weeks or switch to 50-100 mg weekly injections. 2 The FDA label for testosterone enanthate specifically states that doses above 400 mg per month are rarely required, and this patient is receiving 400 mg monthly while achieving levels well above target. 2

Why This Matters for Safety

• Hematocrit monitoring is critical: Testosterone therapy causes dose-dependent increases in hemoglobin, with older men (like this 75-year-old) experiencing greater increases than younger men 1. Recent comparative data shows that 200 mg biweekly dosing carries significantly higher risk of hematocrit rising above 54% compared to 100 mg weekly (8% vs 1%, p=0.023) 3

• Current levels indicate excessive dosing: A total testosterone of 889 ng/dL measured midway between injections suggests peak levels are even higher, increasing risk of erythrocytosis, cardiovascular effects, and other adverse events 1

Required Workup Now

Hematocrit Assessment (Priority #1)

• Check hematocrit immediately - if >54%, stop therapy until it decreases to safe levels, evaluate for hypoxia and sleep apnea, then reinitiate at reduced dose 1
• If hematocrit is 50-54%, proceed with dose reduction and recheck in 3 months
• Baseline hematocrit >50% is a relative contraindication to continued therapy at current dose 1

Prostate Monitoring

At age 75, this patient requires:

• Digital rectal examination
• PSA level - check now if not done in past 3-6 months 1
• Obtain urology consultation if PSA >4.0 ng/mL, PSA increase >1.4 ng/mL in any 12-month period, PSA velocity >0.4 ng/mL/year, prostatic abnormality on exam, or urinary symptoms (AUA/IPSS >19) 1, 4

Additional Safety Labs

• Lipid panel - testosterone can alter serum cholesterol; use caution in patients with cardiac history 2
• Liver function tests - baseline monitoring recommended 2

Estradiol Level Interpretation

The estradiol of 43 pg/mL is within normal range for men on testosterone therapy. While some patients develop estradiol-related symptoms (gynecomastia, fluid retention, mood changes), routine aromatase inhibitor use is not recommended unless symptomatic 5, 6. The estradiol level reflects aromatization of the supraphysiologic testosterone dose and should normalize with dose reduction.

Recent data shows that changes in estradiol concentrations during testosterone therapy have substantial non-linear effects on free testosterone fraction - small changes in estradiol exert larger effects than equivalent changes in testosterone itself 6. This supports addressing the root cause (excessive testosterone dosing) rather than adding aromatase inhibitors.

Monitoring Schedule After Dose Adjustment

1. Recheck testosterone level in 3 months - measure midway between injections, targeting 400-700 ng/dL 1
2. Recheck hematocrit in 3 months, then annually if stable 1
3. Assess symptom response - evaluate whether hypogonadal symptoms remain controlled at lower dose 1
4. Annual monitoring thereafter: testosterone level, hematocrit, PSA/DRE, symptom assessment 1

Timing of Blood Draw Matters

For injectable testosterone enanthate/cypionate, always measure testosterone midway between injections 1, 4. If levels are >700 ng/dL at trough (just before next injection), adjust dose or frequency. If <400 ng/dL at mid-cycle, increase dose 1.

Common Pitfall to Avoid

Do not continue current dosing simply because the patient "feels good." Supraphysiologic testosterone levels increase risks of erythrocytosis (potentially leading to thrombotic events), cardiovascular complications, and other adverse effects that may not produce immediate symptoms 1, 3. The goal is physiologic replacement in the mid-normal range, not optimization to high-normal or supranormal levels.

Weekly dosing (100 mg weekly) may provide more stable levels and fewer peak-related adverse effects compared to biweekly dosing, though both are acceptable if levels remain in target range 5, 3.